Literature DB >> 1623075

Varied presentations and responses to treatment of infections caused by Mycobacterium haemophilum in patients with AIDS.

L L Dever1, J W Martin, B Seaworth, J H Jorgensen.   

Abstract

We describe three patients with AIDS who developed clinically significant infection with Mycobacterium haemophilum. One patient had skin and bone involvement and suspected laryngeal involvement; the second had extensive abdominal adenopathy with partial bowel obstruction; and the third presented with limited skin involvement. Each patient responded transiently to antimycobacterial therapy, but disease recurred and progressed in all three cases. Recovery of M. haemophilum requires a high level of clinical suspicion and special handling of mycobacterial cultures by the microbiology laboratory, including cultivation on enriched chocolate agar or heme-supplemented media and incubation at 30 degrees C for up to 8 weeks. Characteristic patterns of drug susceptibility for this organism have been only partially defined. Reported responses to antimycobacterial therapy in AIDS patients with M. haemophilum infection have been poor, and the optimal therapeutic regimen is not yet known. The prognosis for recovery appears to depend heavily on host-related factors, particularly the degree of immunosuppression.

Entities:  

Mesh:

Year:  1992        PMID: 1623075     DOI: 10.1093/clinids/14.6.1195

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

1.  Optimal detection and identification of Mycobacterium haemophilum in specimens from pediatric patients with cervical lymphadenopathy.

Authors:  Z Samra; L Kaufmann; A Zeharia; S Ashkenazi; J Amir; J Bahar; U Reischl; L Naumann
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 2.  Epidemiology of infection by nontuberculous mycobacteria.

Authors:  J O Falkinham
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

3.  Mycobacterium haemophilum as a novel etiology of cervical lymphadenitis in an otherwise healthy adult patient.

Authors:  Theobald J C Minani; Michael A Saubolle; Edwin Yu; Zdenek Sussland
Journal:  J Clin Microbiol       Date:  2010-05-19       Impact factor: 5.948

Review 4.  Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans.

Authors:  M A Saubolle; T E Kiehn; M H White; M F Rudinsky; D Armstrong
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 5.  Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections.

Authors:  Jerome A Lindeboom; Lesla E S Bruijnesteijn van Coppenraet; Dick van Soolingen; Jan M Prins; Eduard J Kuijper
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

6.  Direct identification of Mycobacterium haemophilum in skin lesions of immunocompromised patients by PCR-restriction endonuclease analysis.

Authors:  S X Wang; L H Sng; H N Leong; B H Tan
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

Review 7.  Mycobacterium haemophilum: an emerging pathogen.

Authors:  T E Kiehn; M White
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

8.  Restriction fragment length polymorphism analysis of clinical isolates of Mycobacterium haemophilum.

Authors:  K Kikuchi; E M Bernard; T E Kiehn; D Armstrong; L W Riley
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

9.  Intracellular growth and cytotoxicity of Mycobacterium haemophilum in a human epithelial cell line (Hec-1-B).

Authors:  L J Fischer; F D Quinn; E H White; C H King
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

10.  Activities of antimicrobial agents against clinical isolates of Mycobacterium haemophilum.

Authors:  E M Bernard; F F Edwards; T E Kiehn; S T Brown; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.